Aulos: Tackling the IL-2 space with computational biology

Apple Tree Partners launched Aulos into the crowded IL-2 space last week with a $40 million series A round and a computationally designed IL-2-binding antibody it thinks could have an edge in efficacy and safety.

Recombinant forms of IL-2 have been used for decades to treat melanoma, but toxicity is high due to the effects of the cytokine on blood vessels and the lungs...